Literature DB >> 1901833

Serological markers as prognostic criteria for the course of HIV infection.

A Kleinschmidt1, A Matuschke, F D Goebel, V Erfle, R Hehlmann.   

Abstract

576 serum samples from 139 HIV infected patients were analyzed for the presence of HIV antigens, as well as anti-core, anti-env and neutralizing antibodies. The results were correlated with the clinical and immunological stages of the patients. While almost all sera were positive for anti-env antibodies, only two thirds of the same sera had antibodies to core proteins. The average antibody titres, particularly of anti-core antibodies, decreased with the onset of clinical symptoms. The presence of p24 antigen could be demonstrated in only 16% of the sera. A positive reaction for core antigen seemed to be correlated with the absence of anti-core antibodies. Env specific neutralizing antibodies were found to be present in all of the sera analyzed in the LC5-test with a maximum neutralizing capacity observed in sera from WR 4 patients. A useful serological marker must fulfil two criteria, namely positive reactivity in the majority of sera examined and a broad range of antibody titres. None of the above described parameters meet these demands. Here we describe the search for new antibody markers, for example antibodies directed against HIV regulatory proteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901833     DOI: 10.1007/bf01644474

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Infection of human fibroblasts and osteoblast-like cells with HIV-1.

Authors:  W Mellert; A Kleinschmidt; J Schmidt; H Festl; S Emler; W K Roth; V Erfle
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

Review 2.  Markers for progression in HIV infection.

Authors:  J M Lange; F de Wolf; J Goudsmit
Journal:  AIDS       Date:  1989       Impact factor: 4.177

3.  HIV isolation from plasma of HIV-infected persons.

Authors:  L A Falk; D Paul; A Landay; H Kessler
Journal:  N Engl J Med       Date:  1987-06-11       Impact factor: 91.245

4.  Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus.

Authors:  A M Prince; D Pascual; L B Kosolapov; D Kurokawa; L Baker; P Rubinstein
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

5.  Antibody response to the viral negative factor (nef) in HIV-1 infection: a correlate of levels of HIV-1 expression.

Authors:  P Reiss; A de Ronde; J M Lange; F de Wolf; J Dekker; C Debouck; J Goudsmit
Journal:  AIDS       Date:  1989-04       Impact factor: 4.177

6.  Expression of the protein encoded by the 3' open reading frame of human T-cell lymphotropic virus type III in bacteria: demonstration of its immunoreactivity with human sera.

Authors:  G Franchini; M Robert-Guroff; F Wong-Staal; J Ghrayeb; I Kato; T W Chang; N T Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

7.  Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.

Authors:  A Ranki; S H Weiss; S L Valle; J Antonen; K J Krohn
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

8.  Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression.

Authors:  P Reiss; A De Ronde; J M Lange; F De Wolf; J Dekker; S A Danner; C Debouck; J Goudsmit
Journal:  AIDS Res Hum Retroviruses       Date:  1989-12       Impact factor: 2.205

9.  Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14.

Authors:  S Dewhurst; J E Embretson; D C Anderson; J I Mullins; P N Fultz
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

10.  Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis.

Authors:  J N Weber; P R Clapham; R A Weiss; D Parker; C Roberts; J Duncan; I Weller; C Carne; R S Tedder; A J Pinching
Journal:  Lancet       Date:  1987-01-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.